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Abstract
Introduction: Thyroid axis abnormalities are common in obese patients. Their contribution in the development of metabolic obesity 
complications remains unclear.
Aim of study: To assess the influence of thyroid axis dysfunction on the occurrence of metabolic obesity complications. 
Material and methods: A cross-sectional review of the thyroid function in 100 obese patients (59 girls and 41 boys, mean age 
13.5 years) with alimentary obesity (mean standardised body mass index [BMI SDS] in boys 4.175 and girls 4.723) complicated by 
metabolic syndrome (MS) diagnosed on the basis of the IDF 2006 criteria (MS, 25 patients) and uncomplicated (75 patients). TSH, 
fT4, fT3 thyroid peroxidase antibodies (TPOAb), and thyroglobulin antibodies (TGAb) were assessed in a single fasting blood sample.
Results: There was no case of overt thyroid disease within the whole analysed group. There were no significant differences in mean 
TSH, fT4, and fT3 levels in patients with and without MS (2.7 µIU/ml vs. 3.0 µIU/ml, 14.5 vs. 14.0 pmol/l, and 5.6 vs. 6.2, respec-
tively; p > 0.05). In the MS group only two patients (8%) presented with a TSH level above the upper limit of the normal range; in the 
group without MS elevated TSH was noticed in 18 (24%) patients. The maximal value of TSH (10.44 µIU/ml) was noticed in one boy 
without MS. Positive TPOAb and/or TGAb were present in 11% of all patients: two patients (8%) with MS and nine (12%) without MS. 
Conclusions: Isolated increased TSH level is common in obese adolescents, although there is no correlation between TSH, fT3, and 
fT4 levels and BMI SDS value. Isolated increased TSH level is not associated with the occurrence of MS in obese adolescents. The 
occurrence of asymptomatic autoimmune thyroiditis (AITD) in obese adolescents is more common than in the general population. 
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Streszczenie
Wstęp: Zaburzenia funkcji osi tarczycowej są częste u pacjentów otyłych. Ich znaczenie w rozwoju metabolicznych powikłań oty-
łości pozostaje niejasny.  
Cel badania: Ocena wpływu zaburzeń funkcji tarczycy u pacjentów otyłych na wystąpienie u nich powikłań metabolicznych. 
Materiały i metody: Ocena funkcji tarczycy w grupie 100 pacjentów (59 dziewcząt, 41 chłopców; średni wiek 13,5 roku) z otyłością 
prostą (średni BMI SDS u chłopców 4,175 i u dziewcząt 4,723) z zespołem metabolicznym rozpoznanym na podstawie kryteriów IDF 
2007 ZM (ZM, 25 pacjentów) i bez. U wszystkich wykonano oznaczenie stężeń TSH, fT4, fT3 przeciwciał przeciw tyreoperoksydazie 
tarczycowej (TPOAb) i przeciwciał przeciwko tyreoglobulinie (TGAb) w pojedynczej próbce krwi. 
Wyniki: W analizowanej grupie nie stwierdzono przypadku jawnej niedoczynności tarczycy. Nie było istotnych statystycznie różnic 
(p > 0,05) średniej wartości TSH, fT4 i fT3 u pacjentów z ZM i bez ZM (odpowiednio: 2,7 µIU/ml vs 3,0 µIU/ml, 14,5 vs 14,0 pmol/l 
i 5,6 vs 6,2 pmol/l). W grupie spełniającej kryteria ZM (n = 25) tylko dwie osoby (2/25; 8%) miały stężenie TSH powyżej górnej gra-
nicy normy (N: 0,3–4,0 µIU/ml). W grupie bez ZM zwiększone stężenie TSH stwierdzono u 18 (18/75; 24%) pacjentów. Maksymalną 
wartość TSH (10,44 µIU/ml) odnotowano u chłopca bez ZM. Dodatnie miano przeciwciał przeciwtarczycowych (TPOAb i/lub TGAb) 
było obecne u 11% pacjentów: 2 pacjentów (2/25; 8%) z ZM i u 9 (9/75; 12%) bez ZM. 
Wnioski: Izolowane zwiększenie stężenia TSH jest częste u otyłych nastolatków, chociaż nie występuje zależność pomiędzy stęże-
niem TSH, fT3 ani fT4 a wartością BMI SDS. Izolowane zwiększenie stężenia TSH  nie ma związku z występowaniem ZM u młodzieży.
Słowa kluczowe: 
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Introduction
Obesity and its consequences have become a  significant 
health problem nowadays. By 2030 an estimated 38% of the 
world’s adult population will be overweight, and another 20% will 
be obese [1]. This phenomenon is associated with increased 
morbidity because excessive fat tissue is a source of many reg-
ulatory factors. Fat tissue hormones and cytokines can directly 
and indirectly affect many of the body’s functions. One of them 
is the thyroid axis. Obese people are often found to present in-
creased thyrotropin (TSH) concentration levels and changes in 
the ratio between the thyroid hormones: triiodothyronine and 
thyroxine, although both levels are usually within the normal 
range [2-4]. The aetiology of these processes is still unclear. It 
is hypothesised that at least four mechanisms are involved in 
this phenomenon: 1) an adaptive process to increased leptin 
production by fat tissue, 2) insulin resistance and concomitant 
chronic low-grade inflammation leading to abnormal mitochon-
drial function and abnormal pattern of energy expenditure, 
3) abnormal activity of deiodinases and relative thyroid hormone 
resistance, and 3) development of autoimmune thyroid disease 
(AITD) [2-6]. The first three mentioned effects seem to be re-
versible after weight reduction, leading to normalisation of free 
triiodothyronine (fT3) and free thyroxine (fT4) ratio. The effect of 
weight reduction on normalisation of TSH remains controversial 
[7, 8]. Although the clinical implications of thyroid axis dysfunc-
tion in obesity are not well investigated, some studies suggest 
that they may contribute to the worsening of metabolic compli-
cations [2]. According to some studies, thyroid dysfunction can 
be an additional risk factor that should be taken into consider-
ation when calculating individual cardiometabolic risk [9]. 
The aim of the study was to assess the influence of thy-
roid axis dysfunction on the occurrence of metabolic obesity 
complications. For this purpose, we compared the thyroid axis 
function in adolescents with uncomplicated nutritional obesity 
and obesity complicated by the occurrence of metabolic syn-
drome (MS).
Material and methods
The study included 100 patients (59 girls and 41 boys) 
between five and 18 years of age (mean age 13.5 years) with 
alimentary obesity (mean standardised body mass index 
[BMI SDS] in boys 4.175 and in girls 4.723) and without history 
of thyroid diseases. Patients were recruited from the Clinic of 
Paediatric and Adolescent Endocrinology University Children’s 
Hospital in Krakow, Poland. In all patients, evaluation was per-
formed before starting the process of weight reduction. BMI was 
calculated from the following equation: BMI = body weight (kg)/ 
body height (m)2. Obesity was defined by BMI above the 95th 
percentile for sex and age [10]. Hypertension was diagnosed 
when systolic and/or diastolic value was above the 95th per-
centile according to sex and height [10]. MS was diagnosed 
on the basis of the IDF 2006 criteria [10]. Glucose, HDL-cho-
lesterol, and triglyceride concentrations were measured in 
blood samples collected after eight hours of fasting. TSH, fT4, 
fT3, thyroid peroxidase antibodies (TPOAb), and thyroglobulin 
antibodies (TGAb) were determined in a single fasting blood 
sample. Normal ranges were defined as: TSH 0.3-4.0 µIU/ml, 
fT4 10-25 pmol/l, fT3 3.0-8.1 pmol/l, TPOAb < 30 IU/ml, and 
TGAb < 30 IU/ml. TSH, fT3, and fT4 were measured using im-
munochemistry method with an Advia Centaur machine, and 
TPOAb and TGAb using radioimmunoassay (RIA) method with 
a Brams machine. 
Statistical analysis
To compare the two sets of data, Student’s t-test or two-
sided Mann-Whitney U test was used. For a correlation analy-
sis, the correlation coefficient (R) and regression analysis were 
used. Statistically significant results were assumed for which 
the probability value was less than 0.05.
Results
There was no case of overt hypothyroidism within the whole 
analysed group. We did not notice abnormal values of fT3 or 
fT4. There were no significant differences in mean TSH, fT4, 
and fT3 levels in patients with and without MS (2.7 µIU/ml vs. 
3.0 µIU/ml, 14.5 vs. 14.0 pmol/l, and 5.6 vs. 6.0 pmol/l, respec-
tively; p > 0.05) (Fig. 1). There was no significant correlation be-
tween BMI SDS and TSH, fT4, or fT3 levels  (R = 0.008; –0.04; 
–0.03, respectively; p > 0.05) (Fig. 2). In the group that met IDF 
criteria of MS (n = 25) only two (2/25, 8%) presented with TSH 
above the upper limit of the normal range. For comparison, in 
the group without MS elevated TSH was noticed in 18 (18/75, 
24%) patients. Sub analysis performed for girls and boys re-
vealed that among girls with MS two (2/14, 14%) presented 
with elevated TSH value vs. 11 (11/4524%) in the group without 
MS. In boys with MS no one presented with elevated TSH value 
vs. seven (7/30, 23%) in the group without MS. The differences 
were not significant. The maximal value of TSH (10.44 uIU/ml) 
was noticed in one boy without MS. Positive antithyroid auto-
antibodies (TPOAb and/or TGAb) were present in 11% of all 
patients: 2 patients (2/25, 8%) with MS (both girls, both with 
normal TSH) and 9 (9/75, 12%) without MS (2 with elevated TSH 
[boys only], seven with normal TSH [5 girls]). Elevated TSH was 
not associated with autoimmunity, and only two patients with 
higher TSH were positive for antithyroid antibodies.
Discussion
Thyroid axis function in obese patients has been inves-
tigated widely in recent years. It has been shown that TSH 
level above upper laboratory normal range is more prevalent 
in obese patients than in healthy pears. According to literature 
data, 10-24% of obese children and adolescents present with 
elevated TSH in the absence of thyroid disease [3, 13], similarly 
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as in the present study (20%). Although the mechanism of such 
an increase in TSH level in obese patients remains unclear, 
it is usually not caused by primary thyroid dysfunction (as in 
subclinical/overt hypothyroidism). In adults the TSH value in-
creases proportionally to the degree of obesity [14-16]. Such 
a correlation is uncertain in children because the literature data 
are conflicting. For example, Jin et al. found positive correlation 
between BMI and serum concentration of TSH in children and 
adolescents [13]. On the other hand, Aeberli et al. concluded 
that TSH was not correlated with body weight, BMI SDS, lean 
body mass, or body fat percentage in this group of patients 
[17]. The correlation between TSH level and BMI SDS was not 
confirmed by our results (Fig. 2). Although we did not show a di-
rect relationship between fat tissue excess and TSH value; the 
literature data indicate a relationship between its metabolic ac-
tivity and the thyroid axis function.  It was postulated that obese 
patients have more frequently elevated level of TSH because 
of resistance in TSH receptor caused by leptin and insulin re-
sistance [18-19], but these studies were conducted on obese 
women and pregnant women, so conclusions probably should 
not be generalised. Even less is known about any clinical con-
sequences of such a phenomenon. It has been postulated that 
thyroid axis disturbances could be an additional marker of car-
diometabolic risk [9]. Moreover, Erdogan et al. found that MS in 
adults was more common in patients with overt hypothyroidism 
in comparison with euthyroid participants and ones with sub-
clinical hypothyroidism [20]. There have been no such studies 
in children and adolescents to date. The results of the present 
study do not confirm any association between abnormal thyroid 
axis function (measured as TSH, fT3, and fT4 levels) and the 
presence of MS in adolescents. No frequent occurrence of overt 
thyroid diseases was confirmed in that group either. Such an in-
creased incidence reported by research carried out on adults 
pointed to a potential association between elevated TSH and 
insulin sensitivity [21]. On the basis of the results of newer pub-
lications, the direction of this dependence seems to be the op-
posite: the insulin resistance in obesity seems to lead to tissue 
hypothyroidism and subsequent increase in TSH synthesis [2]. 
Figure 1. TSH (A), fT3 (B), and fT4 (C) values in patients without 
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The relationship between thyroid function and components of 
MS has been discussed in a  few articles only, with conflict-
ing conclusions [22-24]. Ruhla et al. reported that even a high 
normal TSH level is associated with greater susceptibility to 
MS  [22]. Other studies, conversely, revealed no association 
between TSH fT4 and fT3 levels and MS occurrence, similarly 
to our observation [23-24]. Another aspect analysed in our 
study was the association of obesity and its metabolic com-
plications with AITD. Some studies point to a potential role of 
obesity as an environmental factor contributing to the onset 
and progression of AITD [25]. For example, Hashimoto thy-
roiditis seems to be more prevalent in patients with polycys-
tic ovary syndrome, in which the development of basic mo-
tions has insulin resistance [26]. Adipokines, such as leptin 
and adiponectin, seem to play roles in regulating immunity 
and be links between obesity and autoimmunity [25, 27-34]. 
Moreover, some authors suggest that a hypoechogenic thyroid 
ultrasound image, frequently observed in obese patients, may 
be the early sign of a seronegative AITD and could precede 
the generation of antithyroid antibodies [3]. On the other hand, 
many studies deny increased incidence of AITD in obese pa-
tients with elevated TSH [34-38]. In the study by Gherghereh-
chi et al. among patients with obesity and increased TSH lev-
els, only 10.7% were positive for antithyroid antibodies [39]. In 
our group 11% of patients presented with positive antithyroid 
autoantibodies, which is more than previously reported for an 
obese Italian population (7% of obese adolescents in the pa-
per by Grandone et al.) and almost 10 times more often than 
reported for the normal weight population (1.2%) [5, 40]. The 
main limitation of our study is its small sample size. All compo-
nents of MS can be influenced by different factors, e.g. genetic 
and environmental factors, not only TSH, so it is hard to be 
sure about its causality. Also, we did not interview our patients 
about their daily habits (diet, exercise), and these factors could 
also influence the results. Further clinical, longitudinal studies 
should be performed to investigate whether thyroid status 
plays a role in the occurrence of MS or not.
Conclusions
Isolated, increased TSH levels can be found in a significant 
percentage of obese adolescents. There is no correlation be-
tween TSH, fT3, and fT4 levels and BMI SDS value. Isolated, 
increased TSH level is not associated with the occurrence of 















Figure 2. Correlation between BMI SDS and TSH level [µIU/ml], 
r = 0.008; p > 0.05
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